Recent clinical trials designed to assess the effectiveness of the c-Abl inhibitor, Imatinib, which revolutionized the treatment and clinical outcomes for patients with chronic myelogenous leukemia (CML) [17, 18], failed to provide similar benefits in breast cancer patients, many of whom experienced significant toxicity and disease progression in response to Imatinib administration [19–21]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.